An update on cyclooxygenase-2 expression and metabolites in the kidney

Current Opinion in Nephrology and Hypertension

Volumn 17, Issue 1, 2008, Pages 64-69

  Harris, Raymond C ^a,b,c  

^a VANDERBILT UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin; Cyclooxygenase 2; Hypertension; Prostaglandin; Renin

Indexed keywords

ACETAZOLAMIDE; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BENZOLAMIDE; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG METABOLITE; HYDROCHLOROTHIAZIDE; NITRIC OXIDE; ROFECOXIB; SPIRONOLACTONE;

CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COLORECTAL ADENOMA; DOPAMINERGIC SYSTEM; ENZYME ACTIVITY; HUMAN; HYPERTENSION; KIDNEY; KIDNEY FUNCTION; KIDNEY MEDULLA; MACULA DENSA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANIMALS; CYCLOOXYGENASE 2; DOPAMINE; HUMANS; KIDNEY; KIDNEY DISEASES; NITRIC OXIDE; RENIN-ANGIOTENSIN SYSTEM;

EID: 37349130584     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3282f1bb7d     Document Type: Review

References (68)

1. Harris RC, McKanna JA, Akai Y, et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994; 94:2504-2510.
2. Harris RC. COX-2 and the kidney. J Cardiovasc Pharmacol 2006; 47 (Suppl 1): S37-S42.
3. Yang T, Singh I, Pham H, et al. Regulation of cyclooxygenase expression in the kidney by dietary salt intake. Am J Physiol 1998; 274:F481-F489.
4. Cheng HF, Wang JL, Zhang MZ, et al. Angiotensin II attenuates renal cortical cyclooxygenase-2 expression. J Clin Invest 1999; 103:953-961.
5. Mann B, Hartner A, Jensen BL, et al. Furosemide stimulates macula densa cyclooxygenase-2 expression in rats. Kidney Int 2001; 59:62-68.
6. Harding P, Carretero OA, Beierwaltes WH. Chronic cyclooxygenase-2 inhibition blunts low sodium-stimulated renin without changing renal haemodynamics. J Hypertens 2000; 18:1107-1113.
7. Wang JL, Cheng HF, Harris RC. Cyclooxygenase-2 inhibition decreases renin content and lowers blood pressure in a model of renovascular hypertension. Hypertension 1999; 34:96-101.
8. Schnermann J. Juxtaglomerular cell complex in the regulation of renal salt excretion. Am J Physiol 1998; 274:R263-R279.
9. Cheng HF, Wang JL, Zhang MZ, et al. Role of p38 in the regulation of renal cortical cyclooxygenase-2 expression by extracellular chloride [see comments]. J Clin Invest 2000; 106:681-688.
10. Yang T, Park JM, Arend L, et al. Low chloride stimulation of PGE2 release and COX-2 expression in a mouse Macula densa cell line. J Biol Chem 2000; 275:37922-37929.
11. Cheng HF, Harris RC. Cyclooxygenase-2 expression in cultured cortical thick ascending limb of Henle increases in response to decreased extracellular ionic content by both transcriptional and posttranscriptional mechanisms. Role of p38-mediated pathways. J Biol Chem 2002; 277:45638-45643.
12. Peti-Peterdi J, Komlosi P, Fuson AL, et al. Luminal NaCl delivery regulates basolateral PGE2 release from macula densa cells. J Clin Invest 2003; 112:76-82.
13. Zhang MZ, Yao B, McKanna JA, Harris RC. Cross talk between the intrarenal dopaminergic and cyclooxygenase-2 systems. Am J Physiol Renal Physiol 2005; 288:F840-F845.
14. Prieto-Carrasquero MC, Harrison-Bernard LM, Kobori H, et al. Enhancement of collecting duct renin in angiotensin II-dependent hypertensive rats. Hypertension 2004; 44:223-229.
15. Rohrwasser A, Ishigami T, Gociman B, et al. Renin and kallikrein in connecting tubule of mouse. Kidney Int 2003; 64:2155-2162.
16. Harris RC. Macula densa signalling: a potential role of cyclooxygenase-2 (COX-2)? Nephrol Dial Transplant 2000; 15:1504-1506.
17. Fujino T, Nakagawa N, Yuhki K, et al. Decreased susceptibility to renovascular hypertension in mice lacking the prostaglandin I2 receptor IP. J Clin Invest 2004; 114:805-812.
18. Cheng HF, Wang JL, Zhang MZ, et al. Genetic deletion of COX-2 prevents increased renin expression in response to ACE inhibition. Am J Physiol Renal Physiol 2001; 280:F449-F456.
19. Yang T, Endo Y, Huang YG, et al. Renin expression in COX-2-knockout mice on normal or low-salt diets. Am J Physiol Renal Physiol 2000; 279:F819-F825.
20. Athirakul K, Kim HS, Audoly LP, et al. Deficiency of COX-1 causes natriuresis and enhanced sensitivity to ACE inhibition. Kidney Int 2001; 60:2324-2329.
21. Cheng HF, Wang SW, Zhang MZ, et al. Prostaglandins that increase renin production in response to ACE inhibition are not derived from cyclooxygenase-1. Am J Physiol Regul Integr Comp Physiol 2002; 283:R638-R646.
22. ••] indicate that macula densa-derived COX-2 serves as a tonic modulator or juxtaglomerular renin expression.
23. ••] indicate that macula densa-derived COX-2 serves as a tonic modulator or juxtaglomerular renin expression.
24. Nusing RM, Treude A, Weissenberger C, et al. Dominant role of prostaglandin E2 EP4 receptor in furosemide-induced salt-losing tubulopathy: a model for hyperprostaglandin E syndrome/antenatal Bartter syndrome. J Am Soc Nephrol 2005; 16:2354-2362.
25. Friis UG, Stubbe J, Uhrenholt TR, et al. Prostaglandin E2 EP2 and EP4 receptor activation mediates cAMP-dependent hyperpolarization and exocytosis of renin in juxtaglomerular cells. Am J Physiol Renal Physiol 2005; 289:F989-F997.
26. Schweda F, Klar J, Narumiya S, et al. Stimulation of renin release by prostaglandin E2 is mediated by EP2 and EP4 receptors in mouse kidneys. Am J Physiol Renal Physiol 2004; 287:F427-F433.
27. Qi Z, Cai H, Morrow JD, Breyer MD. Differentiation of cyclooxygenase 1- and 2-derived prostanoids in mouse kidney and aorta. Hypertension 2006;48:323-328.
28. Zhang MZ, Yao B, Cheng HF, et al. Renal cortical cyclooxygenase 2 expression is differentially regulated by angiotensin II AT(1) and AT(2) receptors. Proc Natl Acad Sci U S A 2006; 103:16045-16050. This study demonstrates that while AT1 receptors can inhibit macula densa COX-2 expression, AT2 receptors stimulate expression.
29. Gimonet V, Bussieres L,Medjebeur AA, et al. Nephrogenesis and angiotensin II receptor subtypes gene expression in the fetal lamb. Am J Physiol 1998; 274:F1062-F1069.
30. Kovacs G, Peti-Peterdi J, Rosivall L, Bell PD. Angiotensin II directly stimulates macula densa Na-2Cl-K cotransport via apical AT(1) receptors. Am J Physiol Renal Physiol 2002; 282:F301-F306.
31. Kaneshiro Y, Ichihara A, Takemitsu T, et al. Increased expression of cyclooxygenase-2 in the renal cortex of human prorenin receptor gene-transgenic rats. Kidney Int 2006; 70:641-646. This study shows that the prorenin receptor is expressed in macula densa and implicates prorenin receptor activation in macula densa COX-2 expression.
32. Nguyen G. Increased cyclooxygenase-2, hyperfiltration, glomerulosclerosis, and diabetic nephropathy: put the blame on the (pro)renin receptor? Kidney Int 2006; 70:618-620. This study also shows that the prorenin receptor is expressed in macula densa and implicate prorenin receptor activation in macula densa COX-2 expression.
33. Roig F, Llinas MT, Lopez R, Salazar FJ. Role of cyclooxygenase-2 in the prolonged regulation of renal function. Hypertension 2002; 40:721-728.
34. Catella-Lawson F, McAdam B, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999; 289:735-741.
35. Svendsen KB, Bech JN, Sorensen TB, Pedersen EB. A comparison of the effects of etodolac and ibuprofen on renal haemodynamics, tubular function, renin, vasopressin and urinary excretion of albumin and alpha-glutathione-S- transferase in healthy subjects: a placebo-controlled cross-over study. Eur J Clin Pharmacol 2000; 56:383-388.
36. Rossat RJ, Maillard M, Nussberger J, et al. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999; 66:76-84.
37. Swan SK, Rudy DW, Lasseter KC, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med 2000; 133:1-9.
38. Whelton A. Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics. Am J Ther 2000; 7:63-74.
39. Cheng HF, Zhang MZ, Harris RC. Nitric oxide stimulates cyclooxygenase-2 in cultured cTAL cells through a p38-dependent pathway. Am J Physiol Renal Physiol 2006; 290:F1391-F1397.
40. Deng A, Wead LM, Blantz RC. Temporal adaptation of tubuloglomerular feedback: Effects of COX-2. Kidney Int 2004; 66:2348-2353.
41. Jose PA, Eisner GM, Felder RA. Dopamine and the kidney: a role in hypertension? Curr Opin Nephrol Hypertens 2003; 12:189-194.
42. Ye W, Zhang H, Hillas E, et al. Expression and function of COX isoforms in renal medulla: evidence for regulation of salt sensitivity and blood pressure. Am J Physiol Renal Physiol 2006; 290:F542-F549. This paper demonstrates the importance of medullary COX-2 in regulation of medullary blood flow and sodium excretion.
43. Qi Z, Hao CM, Langenbach RI, et al. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest 2002; 110:61-69.
44. Zewde T, Mattson DL. Inhibition of cyclooxygenase-2 in the rat renal medulla leads to sodium-sensitive hypertension. Hypertension 2004; 44:424-428.
45. Kammerl MC, Nusing RM, Schweda F, et al. Low sodium and furosemideinduced stimulation of the renin system inman ismediated by cyclooxygenase 2. Clin Pharmacol Ther 2001; 70:468-474.
46. Rao R, Zhang MZ, Zhao M, et al. Lithium treatment inhibits renal GSK-3 activity and promotes cyclooxygenase 2-dependent polyuria. Am J Physiol Renal Physiol 2005; 288:F642-F649.
47. Zhang MZ, Sanchez Lopez P, McKanna JA, Harris RC. Regulation of cyclooxygenase expression by vasopressin in rat renal medulla. Endocrinology 2004; 145:1402-1409.
48. Kotnik P, Nielsen J, Kwon TH, et al. Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus. Am J Physiol Renal Physiol 2005; 288:F1053-F1068.
49. Kennedy CR, Xiong H, Rahal S, et al. Urine concentrating defect in prostaglandin EP1-deficient mice. Am J Physiol Renal Physiol 2007; 292: F868-F875. These papers delineate interactions of COX-2-derived prostanoids and vasopressin-mediated water reabsorption.
50. Yao B, Harris RC, Zhang MZ. Interactions between 11beta-hydroxysteroid dehydrogenase and COX-2 in kidney. Am J Physiol Regul Integr Comp Physiol 2005; 288:R1767-R1773.
51. Hocherl K, Endemann D, Kammerl MC, et al. Cyclo-oxygenase-2 inhibition increases blood pressure in rats. Br J Pharmacol 2002; 136: 1117-1126.
52. Yang T. Microsomal prostaglandin E synthase-1 and blood pressure regulation. Kidney Int 2007; 72:274-278.
53. Jia Z, Zhang A, Zhang H, et al. Deletion of microsomal prostaglandin E synthase-1 increases sensitivity to salt loading and angiotensin II infusion. Circ Res 2006; 99:1243-1251.
54. Francois H, Facemire C, Kumar A, et al. Role of microsomal prostaglandin E synthase 1 in the kidney. J Am Soc Nephrol 2007; 18:1466-1475.
55. Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA 2006; 296:1619-1632.
56. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355:873-884.
57. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355:885-895.
58. Komers R, Lindsley JN, Oyama TT, et al. Immunohistochemical and functional correlations of renal cyclooxygenase- 2 in experimental diabetes. J Clin Invest 2001; 107:889-898.
59. Yao B, Xu J, Qi Z, et al. Role of renal cortical cyclooxygenase-2 expression in hyperfiltration in rats with high-protein intake. Am J Physiol Renal Physiol 2006; 291:F368-F374. This paper indicates that COX-2 mediated prostanoids mediate the hyperfiltration seen with chronic administration of a high protein diet.
60. Cheng HF, Wang CJ, Moeckel GW, et al. Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int 2002; 62:929-939.
61. Wang J-L, Cheng H-F, Zhang M-Z, et al. Selective increase of cyclooxygenase-2 expression in a model of renal ablation. Am J Physiol 1998; 275:F613-F622.
62. Komers R, Lindsley JN, Oyama TT, Anderson S. Cyclo-oxygenase-2 inhibition attenuates the progression of nephropathy in uninephrectomized diabetic rats. Clin Exp Pharmacol Physiol 2007; 34:36-41. This paper implicates COX-2-derived prostanoids as mediators of hyperfiltration and renal injury in models of progressive nephron destruction.
63. Sankaran D, Bankovic-Calic N, Ogborn MR, et al. Selective COX-2 inhibition markedly slows disease progression and attenuates altered prostanoid production in Han:SPRD-cy rats with inherited kidney disease. Am J Physiol Renal Physiol 2007; 293:F821-F830. This paper also implicates COX-2 derived prostanoids as mediators of hyperfiltration and renal injury in models of progressive nephron destruction.
64. Hirose S, Yamamoto T, Feng L, et al. Expression and localization of cyclooxygenase isoforms and cytosolic phospholipase A2 in anti-Thy-1 glomerulonephritis. J Am Soc Nephrol 1998; 9:408-416.
65. Martineau LC, McVeigh LI, Jasmin BJ, Kennedy CR. p38 MAP kinase mediates mechanically induced COX-2 and PG EP4 receptor expression in podocytes: implications for the actin cytoskeleton. Am J Physiol Renal Physiol 2004; 286:F693-F701.
66. Cheng H, Wang S, Jo YI, et al. Overexpression of cyclooxygenase-2 predisposes to podocyte injury. J Am Soc Nephrol 2007; 18:551-559.
67. Villanueva S, Cespedes C, Gonzalez AA, et al. Effect of ischemic acute renal damage on the expression of COX-2 and oxidative stress-related elements in rat kidney. Am J Physiol Renal Physiol 2007; 292:F1364-F1371.
68. Patel NS, Cuzzocrea S, Collino M, et al. The role of cycloxygenase-2 in the rodent kidney following ischaemia/reperfusion injury in vivo. Eur J Pharmacol 2007; 562:148-154.